Rheumatoid arthritis Archives -

The first patient has been treated with an implantable bioelectronic device developed by Galvani Therapeutics, set up by

GSK, Verily-backed Galvani starts trials of bioelectronic arthritis therapy

https://pharmaphorum.com/news/gsk-verily-backed-galvani-starts-trials-of-bioelectronic-arthritis-therapy/

News/ News/ Sales and Marketing

Actemra shortage spills over to include Sanofi’s rival Kevzara

Phil Taylor Actemra, coronavirus, COVID-19, drug shortages, Kevzara, Rheumatoid arthritis, Roche, Sanofi 0 Comment

Roche’s Actemra has been in high demand since its value in treating severe COVID-19 was established, leading to

Actemra shortage spills over to include Sanofi’s rival Kevzara

https://pharmaphorum.com/news/actemra-shortage-spills-over-to-include-sanofis-rival-kevzara/

News/ News/ Patients

FDA firms up JAK inhibitor warnings after Xeljanz review

Phil Taylor AbbVie, Eli Lilly, fda, JAK inhibitor, Olumiant, Pfizer, Rheumatoid arthritis, Rinvoq, safety, Xeljanz 0 Comment

The FDA has concluded its safety review of Pfizer’s JAK inhibitor Xeljanz and Xeljanz XR, requiring revised warnings

FDA firms up JAK inhibitor warnings after Xeljanz review

https://pharmaphorum.com/news/fda-firms-up-jak-inhibitor-warnings-after-xeljanz-review/

News/ News/ R&D

Trials leave Galapagos’ SIK programme looking under the weather

Phil Taylor Galapagos, Gilead Sciences, psoriasis, Rheumatoid arthritis, SIK inhibitor, ulcerative colitis 0 Comment

Galapagos has had to send its SIK inhibitor programme back to the drawing board after its lead compound

Trials leave Galapagos’ SIK programme looking under the weather

https://pharmaphorum.com/news/trials-leave-galapagos-sik-programme-looking-under-the-weather/

News/ News/ Sales and Marketing

FDA holds back from action over Xeljanz safety study

Phil Taylor AbbVie, fda, JAK inhibitor, Pfizer, Rheumatoid arthritis, Rinvoq, safety, side effects, Xeljanz 0 Comment

The FDA has said it will wait for additional results from last week’s trial showing an increased risk

FDA holds back from action over Xeljanz safety study

https://pharmaphorum.com/news/fda-holds-back-from-action-over-xeljanz-safety-study/

Market Access/ News/ News

NICE backs broad use for Gilead/Galapagos arthritis pill Jyseleca

Phil Taylor filgotinib, Galapagos, Gilead, HEOR, NHS, NICE, Rheumatoid arthritis 0 Comment

Patients with rheumatoid arthritis (RA) in England will be able to get treatment with Gilead Sciences and Galapagos’

NICE backs broad use for Gilead/Galapagos arthritis pill Jyseleca

https://pharmaphorum.com/news/nice-backs-broad-use-for-gilead-galapagos-arthritis-pill-jyseleca/

News/ News/ Sales and Marketing

Gilead’s rheumatoid arthritis pill approved in Japan

Richard Staines Eisai, filgotinib, Galapagos, Gilead, Jyseleca, Rheumatoid arthritis 0 Comment

Gilead has scored a major approval for its troubled rheumatoid arthritis pill filgotinib, after regulators in Japan granted

Gilead’s rheumatoid arthritis pill approved in Japan

https://pharmaphorum.com/news/gileads-rheumatoid-arthritis-pill-approved-in-japan/

Digital/ Patients/ R&D/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis

Holistic immunology: Supporting patients at every stage of their journey

mike.hammerton@pharmaphorum.com IMID, inflammatory bowel disease, inflammatory diseases, Janssen, Janssen leaders, psoriasis, Rheumatoid arthritis 0 Comment

As part of our series from leaders at Janssen, the company’s Max Pahlow looks at how approaches to

Holistic immunology: Supporting patients at every stage of their journey

https://pharmaphorum.com/r-d/views-analysis-r-d/holistic-immunology-supporting-patients-at-every-stage-of-their-journey/

News/ News/ R&D/ Top stories

Analysts question Gilead’s commitment to arthritis drug after FDA setback

Richard Staines Galapagos, Gilead, inflammatory diseases, Rheumatoid arthritis, ulcerative colitis 0 Comment

The FDA has rejected Gilead and Galapagos’ rheumatoid arthritis (RA) pill filgotinib over concerns that it could damage

Analysts question Gilead’s commitment to arthritis drug after FDA setback

https://pharmaphorum.com/news/gilead-could-become/

Trending

Rheumatoid arthritis

Login